Valeant Pharmaceuticals (VRX) PT to $285 at BMO Capital Following 'Strong and Clean' Quarter

July 24, 2015 7:45 AM

BMO Capital analyst Alex Arfaei reiterated an Outperform rating and boosted his price target on Valeant Pharmaceuticals (NYSE: VRX) to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found